BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33482891)

  • 1. Risk factors for lymphatic filariasis and mass drug administration non-participation in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Wood P; Wangdi K; McBride WJ
    Parasit Vectors; 2021 Jan; 14(1):72. PubMed ID: 33482891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.
    Dickson BFR; Graves PM; Aye NN; Nwe TW; Wai T; Win SS; Shwe M; Douglass J; Bradbury RS; McBride WJ
    PLoS Negl Trop Dis; 2018 Nov; 12(11):e0006944. PubMed ID: 30419025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Thailand eliminated lymphatic filariasis as a public health problem.
    Rojanapanus S; Toothong T; Boondej P; Thammapalo S; Khuanyoung N; Santabutr W; Prempree P; Gopinath D; Ramaiah KD
    Infect Dis Poverty; 2019 May; 8(1):38. PubMed ID: 31130143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic filariasis elimination status: Wuchereria bancrofti infections in human populations and factors contributing to continued transmission after seven rounds of mass drug administration in Masasi District, Tanzania.
    Lupenza ET; Gasarasi DB; Minzi OM
    PLoS One; 2022; 17(1):e0262693. PubMed ID: 35045109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Coverage and Compliance in Mass Drug Administration for the Elimination of LF in Two 'Endgame' Districts in Indonesia Using Micronarrative Surveys.
    Krentel A; Damayanti R; Titaley CR; Suharno N; Bradley M; Lynam T
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005027. PubMed ID: 27812107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards elimination of lymphatic filariasis in southeastern Madagascar: Successes and challenges for interrupting transmission.
    Garchitorena A; Raza-Fanomezanjanahary EM; Mioramalala SA; Chesnais CB; Ratsimbasoa CA; Ramarosata H; Bonds MH; Rabenantoandro H
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006780. PubMed ID: 30222758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of MDA registers for Lymphatic Filariasis: Findings, and potential uses in addressing the endgame elimination challenges.
    de Souza DK; Gass K; Otchere J; Htet YM; Asiedu O; Marfo B; Biritwum NK; Boakye DA; Ahorlu CS
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008306. PubMed ID: 32407319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016.
    Sheel M; Sheridan S; Gass K; Won K; Fuimaono S; Kirk M; Gonzales A; Hedtke SM; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2018 Jul; 12(7):e0006583. PubMed ID: 30011276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic filariasis elimination efforts in Rufiji, southeastern Tanzania: decline in circulating filarial antigen prevalence in young school children after twelve rounds of mass drug administration and utilization of long-lasting insecticide-treated nets.
    Jones C; Ngasalla B; Derua YA; Tarimo D; Malecela MN
    Int J Infect Dis; 2017 Aug; 61():38-43. PubMed ID: 28527817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of microfilaremia in 'hotspots' of four lymphatic filariasis endemic districts of Nepal during post-MDA surveillance.
    Mehta PK; Maharjan M
    PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011932. PubMed ID: 38295107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping and modelling the impact of mass drug adminstration on filariasis prevalence in Myanmar.
    Aye NN; Lin Z; Lon KN; Linn NYY; Nwe TW; Mon KM; Ramaiah K; Betts H; Kelly-Hope LA
    Infect Dis Poverty; 2018 May; 7(1):56. PubMed ID: 29855355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
    Minetti C; Tettevi EJ; Mechan F; Prada JM; Idun B; Biritwum NK; Osei-Atweneboana MY; Reimer LJ
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006994. PubMed ID: 30608931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic filariasis control in Tanzania: infection, disease perceptions and drug uptake patterns in an endemic community after multiple rounds of mass drug administration.
    Derua YA; Kisinza WN; Simonsen PE
    Parasit Vectors; 2018 Jul; 11(1):429. PubMed ID: 30029675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti.
    Boyd A; Won KY; McClintock SK; Donovan CV; Laney SJ; Williams SA; Pilotte N; Streit TG; Beau de Rochars MV; Lammie PJ
    PLoS Negl Trop Dis; 2010 Mar; 4(3):e640. PubMed ID: 20351776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia.
    Titaley CR; Worrell CM; Ariawan I; Taihuttu YMJ; de Lima F; Naz SF; Que BJ; Krentel A
    PLoS Negl Trop Dis; 2022 Nov; 16(11):e0010900. PubMed ID: 36367853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration.
    Rao RU; Nagodavithana KC; Samarasekera SD; Wijegunawardana AD; Premakumara WD; Perera SN; Settinayake S; Miller JP; Weil GJ
    PLoS Negl Trop Dis; 2014; 8(11):e3281. PubMed ID: 25393404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity in elimination efforts could increase the risk of resurgence of lymphatic filariasis in Madagascar.
    Rajaonarifara E; Roche B; Chesnais CB; Rabenantoandro H; Evans M; Garchitorena A
    Infect Genet Evol; 2024 Jun; 120():105589. PubMed ID: 38548211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential factors influencing lymphatic filariasis transmission in "hotspot" and "control" areas in Ghana: the importance of vectors.
    Pi-Bansa S; Osei JHN; Frempong KK; Elhassan E; Akuoko OK; Agyemang D; Ahorlu C; Appawu MA; Koudou BG; Wilson MD; de Souza DK; Dadzie SK; Utzinger J; Boakye DA
    Infect Dis Poverty; 2019 Feb; 8(1):9. PubMed ID: 30717788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-compliance to Mass Drug Administration Associated with the Low Perception of the Community Members About their Susceptibility to Lymphatic Filariasis in Ankobra, Ghana.
    Dicko I; Coulibaly YI; Sangaré M; Sarfo B; Nortey PA
    Infect Disord Drug Targets; 2020; 20(2):167-174. PubMed ID: 30727921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals.
    Karim MJ; Haq R; Mableson HE; Sultan Mahmood ASM; Rahman M; Chowdhury SM; Rahman AKMF; Hafiz I; Betts H; Mackenzie C; Taylor MJ; Kelly-Hope LA
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007542. PubMed ID: 31306409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.